Cosciens Biopharma Inc. · TSX:CSCI
Cosciens Biopharma — Aeterna Zentaris — H.C. Wainwright 23rd Annual Global Investment Conference 2021
27 slides from Cosciens Biopharma's conference presentation, Sep 13, 2021
Slide 1: In Pursuit of Medical Innovations
zentaris.com NASDAQ: AEZS / TSX: AEZS Exhibit 99.1 ALTERNA ZENTARIS In Pursuit of Medical Innovations H.C. Wainwright 23" Annual Global Investment Conference September 13-15, 2021 Dr. Klaus Paulini, Chief Executive Officer
Slide 2: Forward-Looking Statements
Forward-Looking Statements This document contains forward looking statements (as defined by applicable securities legislation) made pursuant to the safe harbor provision of the US Securities Litigation Reform Act of 1995 and forward looking information (as defined under applicable Canadian securitie
Slide 3: Investment highlights
Diversified portfolio focused on areas Leveraging network of large pharmaceutical of significant unmet medical need and university partners and collaborators Executing strategy to deliver multiple Strong financial position with runway development and regulatory milestones expected to fund operations
Slide 4: Diagnostic Commercial and Development Pipeline
Diagnostic Commercial and Development Pipeline Commercial Rights Program Indication Preclinical Phase 1 Phase2 Phase3 Commercial U.S./Canada Europe Israel ROW ) 2 , | Adult Growth Hormone Sa ie Sonsilient MegaPharm) YETERNA bq Macimorelin |p eficiency (AGHD) ——— nov tisk | «@ i wv Gee ZENTARIS fo) ‘
Slide 5: Therapeutic and Vaccine Development Pipeline
Therapeutic and Vaccine Development Pipeline Program Indication Preclinical Phase 1 Phase2 Phase3_© ————————— Program Highlights Neuromyelitis Optica Wee (2) AIM Biologicals Spectrum Disorder [i In-licensed program in January 2021 URZBURG (2) = (NMOSD) a Amyotrophic Lateral 4 rn A Entered material t
Slide 6: Development Programs
Development Programs Advancing Therapeutics and Vaccines to Secure Long-Term Growth ETERNA 6 ZENTARIS
Slide 7: Potential selective treatment option for neuromyelitis optica spectrum disorder (NMOSD)
Potential selective treatment option for neuromyelitis optica spectrum disorder (NMOSD) Maternal Blood and tissue NMOSD is an auto-antibody mediated inflammatory PI CNS orphan disorder with significant unmet medical need affecting 1 per 100,000 people’ Entered exclusive license and R&D agreement wit
Slide 8: AIM Biologicals Concept
AIM Biologicals Concept’ « Adaptable platform of immunomodulating molecules * Soluble fusion proteins el alaem-soeptide (= antigen) Valea is coupled to the proteins via a linker gi é + The proteins interacts with the target cells via the T-cell receptor (TCR) and ILT-2 to induce immune tolerance Bt:
Slide 9: The Promise of Targeted, Physiological, Antigen-Specific Immunomodulation
The Promise of Targeted, Physiological, Antigen-Specific Immunomodulation . x ® v AIM Biologics Autoimmune Immunosuppressive Antigen-specific Diseases Therapeutics Immunomodulation Enhanced by autoreactive Reduce disease symptoms Various antigens may be used for effector T cells highly selective de-
Slide 10: AEZS-150: Delayed Clearance Parathyroid Hormone (DC-PTH) Fusion Polypeptide
AEZS-150: Delayed Clearance Parathyroid Hormone (DC-PTH) Fusion Polypeptide Hypoparathyroidism Body produces abnormally low levels of PTH “~ ap PTHisa key regulating hormone Uy) essential for calcium homeostasis and - Indepth characterization of development candidate renal phosphate clearance L Orph
Slide 11: AEZS-150: Delayed Clearance Parathyroid Hormone (DC-PTH) Fusion Polypeptide
AEZS-150: Delayed Clearance Parathyroid Hormone (DC-PTH) Fusion Polypeptide AEZS-150: Fusion-Protein of PTH [1-34] coupled via a linker to a modified growth-hormone binding protein (GHBP)' Delayed clearance in comparison to PTH[1-34] Potential to control serum calcium levels by once weekly treatment
Slide 12: Oral COVID-19 vaccine platform
aS Immunity (lg) Immunity Vga f INIVERSITAT WURZBURG Orally active live-attenuated bacterial vaccine based on the Salmonella typhi Ty21a carrier strain currently used as a typhoid vaccine This new, alternative and unprecedented approach with Salmonella based vaccines should have the potential to ind
Slide 13: Currently undergoing pre-clinical studies for prevention of coronavirus diseases
Currently undergoing pre-clinical studies for the prevention of coronavirus diseases, including CC) 1 COVI D-19 (SARS-CoV-2) Integration of 1 or 2 erate \ Salmonella typhi Ty21a SARS-CoV-2 antigens = = 2 Stan ” Adaptable Plasmid Vector Induction of Immunity Multiple-Antigens Potential to induce muco
Slide 14: Development Plan Towards Phase 1: Oral Coronavirus Vaccine
Development Plan Towards Phase 1 Oral Coronavirus Vaccine H1 2023: Planned start of clinical development for oral vaccine Pre-clinical safety and toxicology assessment Manufacturing process assessment/ development Virus challenge experiments in immunized transgenic animals In-vivo immunology experim
Slide 15: Macimorelin as potential ALS treatment
_] THE UNIVERSITY ¥ ) OF QUEENSLAND dl AUSTRALIA {{ I y y Exclusive rights for AEZS to Investigation as a potential University researchers to negotiate a license agreement for the treatment for Amyotrophic Lateral Sclerosis (ALS, Lou secure grants and conduct commercial use of the results Gehrig's d
Slide 16: Roadmap for Advancing Development Programs Towards IND Filing
Roadmap for Advancing Development Programs Towards IND Filing ea Clinical Pre-clinical Development ~ > Development Establish Experimental Establish Transfer joint pre- work in-vitro Select Formalized clinical FDA Initiate of program clinical and in-vivo development pre-clinical development _ pre-IND
Slide 17: Macimorelin / Macrilen: A Disruptive Oral Diagnostic Test Solution
ag Macimorelin / Macrilen™ A Disruptive Oral Diagnostic Test Solution for Growth Hormone Deficiency First and only AGHD test approved by US FDA and European Commission AETERNA ZENTARIS
Slide 18: Growth hormone produced by the pituitary gland
Produced by the pituitary gland (located at the base of the brain)
Slide 19: No Other FDA or EC Approved Oral Test
No Other FDA or EC Approved Oral Test Insulin tolerance test (ITT) considered ‘(ITT Test] is increasingly used less the “Gold Standard” in GHD detection frequently in the U.S. because of procedures"? safety concerns.” ? Not FDA or EC approved or regulated 2: AACE 2019 Guidelines: American Associatio
Slide 20: Pediatric macimorelin trial in children and adolescents
Children and adolescents from 2 to less than 18 years of age with G suspected GHD to be enrolled (Years) <18 Open-label, single dose, multicenter, multinational : . 2 100 subjects worldwide US, Czech Republic, Germany, Poland, Georgia, Italy, Serbia, Romania, Russia, Slovenia and Ukraine Macimorelin
Slide 21: Macimorelin Commercial Rights
Macimorelin Commercial Rights Actively seeking commercial partners in ROW a (SS Consilient / ee, Health License Agreement Territories: Europe and the United Kingdom Pricing and reimbursement milestones Royalties on sales Aeterna Zentaris controls supply chain and by) provides finished product accord
Slide 22: Expected Value Driving Milestones
Expected Value Driving Milestones v Commenced pivotal Phase 3 safety and efficacy study a (DETECT-trial) Planned start of clinical - development for oral vaccine ¥ Option exercise and in- licensing of Chlamydia as Planned submission - FDA Planned start of clinical second vaccine indication and EMACG
Slide 23: Corporate Overview
23 Corporate Overview
Slide 24: Cash expected to fund operations beyond 2023
d to fund operations beyond 2023' ~$70M ~$88M ~121M ~1.6M Cash on Hand Market Cap’ Shares — 3 month As of June 30, 2021 Outstanding” Avg. Volume
Slide 25: Management team
Leslie Auld, CPA, Nicola Ammer, MD a Michael Teifel, PhD MBA SVP Clinical < SVP Non-Clinical SVP, Chief Financial Development, " Development, Officer Chief Medical Officer P w Chief Scientific Officer
Slide 26: Investment Summary
Slide 27: In Pursuit of Medical Innovations
zentaris.com NASDAQ: AEZS / TSX: AEZS ALTERNA ZENTARIS In Pursuit of Medical Innovations Investor & Media Relations JTC Team 833.475.8247 aezs@jtcir.com
Aeterna Zentaris — H.C. Wainwright 23rd Annual Global Investment Conference 2021 on 6ix